Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
April 21, 2014 at 16:56 PM EDT
Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin ...